$NXTC you know, almost no matter how good the results NXTC releases, phase 1 trial won't justify the price move on tuesday. If their data about the 11 additional patients is similar to the previous 32, (2/32 responsed to drug), this drug almost certainly won't make it to market.
  • 1
  • 2